Epstein-Barr Virus Induced Gene-2 Upregulation Identifies a Particular Subtype of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
Kerr, Jonathan R · Frontiers in pediatrics · 2019 · DOI
Quick Summary
This study found that about 38-55% of ME/CFS patients have higher levels of a specific gene called EBI2 turned on in their immune cells. Patients with this EBI2 pattern appear to have more severe symptoms and different antibody levels compared to other ME/CFS patients. Because EBI2 is known to affect both immune function and brain function, finding this subtype could help explain why ME/CFS patients experience such different symptoms and may lead to new treatments.
Why It Matters
This research provides objective molecular criteria to identify a subset of ME/CFS patients, potentially enabling better patient stratification for clinical trials and personalized treatment approaches. The identification of EBI2 as a key dysregulated gene links viral infection (EBV) to immune and neurological dysfunction in ME/CFS, suggesting a mechanistic pathway that could be therapeutically targeted with existing drug candidates.
Observed Findings
EBI2 mRNA upregulation was identified in 38-55% of CFS/ME patients studied in peripheral blood mononuclear cells.
Patients with elevated EBI2 expression demonstrated a more severe disease phenotype compared to other ME/CFS patients.
Patients with the EBI2 subtype showed lower levels of EBNA1 IgG antibodies, indicating altered immune response to prior EBV infection.
EBI2 is a negative regulator of innate immune responses in monocytes and is involved in central nervous system function.
Inferred Conclusions
ME/CFS comprises molecularly distinct subtypes, with the EBI2 subtype representing an identifiable and potentially treatable subset.
EBV-triggered EBI2 upregulation may account for the heterogeneous immune and neurological abnormalities observed across ME/CFS patients.
EBI2 antagonists currently in development may have therapeutic potential specifically for patients with the EBI2 subtype.
Remaining Questions
What triggers EBI2 upregulation in some ME/CFS patients but not others, and is EBV infection necessary and/or sufficient for this dysregulation?
How can clinicians most practically and cost-effectively identify the EBI2 subtype in clinical practice to enable targeted treatment?
What This Study Does Not Prove
This study does not establish that EBI2 upregulation causes severe ME/CFS or that EBV directly triggers this gene expression pattern in all cases—it demonstrates correlation in a subgroup. The findings do not prove that EBI2 antagonists will be effective in treating patients with this subtype, only that they warrant investigation. The study does not determine whether EBI2 upregulation is a primary driver or a secondary consequence of disease processes.